Evidence map›Paper›PMID 37701146›Full record

ArticleJBMR plus2023

Hypocitraturia and Risk of Bone Disease in Patients With Kidney Stone Disease.

Calyani Ganesan, I-Chun Thomas, Maria E Montez-Rath, Glenn M Chertow, John T Leppert, Alan C Pao

Open access · goldAbstract read
In one paragraph

Article in JBMR plus, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.0field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Citrate and calcium kidney stones.Clinical kidney journal · 2025
    Review
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Calyani GanesanDepartment of Medicine, Division of Nephrology Stanford University Palo Alto CA USA.ORCID https://orcid.org/0000-0002-4050-9587
I-Chun ThomasDivision of Nephrology and Department of Urology Veterans Affairs Palo Alto Health Care System Palo Alto CA USA.
Maria E Montez-RathDepartment of Medicine, Division of Nephrology Stanford University Palo Alto CA USA.
Glenn M ChertowDepartment of Medicine, Division of Nephrology Stanford University Palo Alto CA USA.ORCID https://orcid.org/0000-0002-7599-0534
John T LeppertDepartment of Medicine, Division of Nephrology Stanford University Palo Alto CA USA.
Alan C PaoDepartment of Medicine, Division of Nephrology Stanford University Palo Alto CA USA.
Palo Alto University · USVA Palo Alto Health Care System · US

Funding

Bone Health in Patients with Urinary Stone DiseaseK23DK128651 · NIDDK · STANFORD UNIVERSITY · PI Calyani Ganesan · 2022 to 2026
$964k
NIDDK NIH HHS K23 DK128651
6 · The paper itself

Abstract

Patients with kidney stone disease are at higher risk for bone disease. Hypocitraturia is common in patients with kidney stone disease and a key risk factor for stone recurrence. In this retrospective cohort study, we sought to determine whether hypocitraturia is also a risk factor for incident bone disease in patients with kidney stone disease. We used nationwide data from the Veterans Health Administration and identified 9025 patients with kidney stone disease who had a 24-hour urine citrate measurement between 2007 and 2015. We examined clinical characteristics of patients by level of 24-hour urine citrate excretion (<200, 200-400, and >400 mg/d) and the time to osteoporosis or fracture according to 24-hour urine citrate excretion level. Almost one in five veterans with kidney stone disease and a 24-hour urine citrate measurement had severe hypocitraturia, defined as <200 mg/d. Patients with severe hypocitraturia were at risk for osteoporosis or fracture (hazard ratio [HR] = 1.23; confidence interval [CI] 1.03-1.48), but after adjustment for demographic factors, comorbid conditions, and laboratory abnormalities associated with hypocitraturia, the association was no longer statistically significant (HR = 1.18; CI 0.98-1.43). Our results in a predominantly male cohort suggest a modest association between hypocitraturia and osteoporosis or fracture; there are likely to be other explanations for the potent association between kidney stone disease and diminished bone health. © 2023 The Authors.

Indexed as

FRACTURE PREVENTION AND GENERAL POPULATION STUDIESFRACTURE RISK ASSESSMENTOSTEOPOROSISSCREENING

Identifiers

PMID37701146
PMCPMC10494504
OpenAlexW4382401644

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.